Ocular Therapeutix awaiting from FDA on Dextenza, says Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $14 price target on Ocular Therapeutix after meeting with its CEO Anthony Mattessich at the Piper Jaffray Healthcare Conference. The discussions were around the “recent Form 483 issuance for Dextenza’s NDA”, writes the analyst, adding that the management has responded to the FDA’s 3 observations in full. Catanzaro further notes that all subsequent communications between the FDA and the company have been “administrative”, stating that Mattessich remains confident that Dextenza will be approved.
https://thefly.com/landingPageNews.php?id=2829495